

# 2010 PUBLICATIONS CATALOG



**INSIGHT PHARMA REPORTS** are used by leading pharmaceutical, biotech, diagnostic, consulting and financial companies to keep abreast of the **LATEST ADVANCES IN PHARMACEUTICAL R&D**, their potential applications and business impacts, and their current and future position in the marketplace.

[InsightPharmaReports.com](http://InsightPharmaReports.com)

## Multiplex Assays: Evolving Technologies, Applications and Future Directions

The report examines the role of multiplex and multi-analyte biomarker assays in translational medicine. We deal with their direct contributions to drug discovery and development; their contributions as theranostics, companion diagnostics, etc.; and the reasons why they are not more prevalent despite their apparent high potential.

- Evolution of multiplex assays and translational medicine
- Multiplex technologies
- Applications (pharma, predicative toxicology and multiplex biomarkers)
- Market-related considerations
- General observations
- Interview transcripts with industry experts

*Published: January 2010*

*Length: 190 pages*

## Strategic Alliances: Synergistic Path to Value Creation

The once insular pharmaceutical industry has been forced to look beyond its walls for drug pipeline candidates. The result has been an almost exponential growth over the past decade in the number and value of strategic alliances. The report analyses in detail the key driving forces behind the growth of strategic alliances and the changing characteristics of such deals, including:

- The pattern of escalating deal valuations
- Typical components of a strategic alliance
- Timely commentary for alliance executives
- Trends for future strategic alliance deals
- Recommendation for the future

*Published: January 2010*

*Length: 120 pages*

## Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response

The report reviews the problems of insufficient efficacy, side effects, and adverse events associated with the small-molecule and biological drugs available today to treat these disorders. These observations have led to an interest in identifying ways to balance the immune reaction, to suppress the part of the immune response that is causing the disease, while maintaining or enhancing other aspects of the immune system

- Approximately 400 product candidates and development programs are identified
- Current and emerging therapies for selected autoimmune or inflammatory disorders and prevention of organ transplant rejection, directed against a wide range of putative targets, are summarized
- Specifically, more than 250 emerging autoimmune disease therapies, 80 asthma therapies in development, and 50+ therapy candidates for allergies are covered
- The strategic consequences of intense competition in a crowded product space are considered
- Interview transcripts with industry experts

*Published: December 2009*

*Length: 400 pages*

## FORTHCOMING REPORTS IN 2010

Immunoinhibitory Pipeline  
Strategy for Next-Generation Therapies  
Combination Rx & Dx  
Animal Models

Protein Production  
Kinase Pipeline  
Repurposing Drugs

GLP Guide  
GCP Guide  
GMP Guide

## **Immunotherapies and Vaccines for Nontraditional Indications**

Research and development of immunotherapies for other indications has been progressing for many years, although this effort has not received the public attention that the work on infectious disease and cancer immunotherapies and vaccines has. Immunotherapies being developed or used for treatment of other diseases (i.e., beyond prevention and treatment of infectious diseases and cancer) are the focus of this report.

- Alzheimer's Disease
- Addictions
- Other neurology indications of monoclonal antibodies and immunotherapies
- Cardiovascular diseases including Thrombosis
- Hematology/blood disorders
- Ophthalmology
- Osteoporosis
- Type 2 Diabetes
- Other applications of antibodies and immunotherapies
- Interview transcripts with industry experts

*Published: December 2009*

*Length: 224 pages*

## **Ion Channel Modulator Pipelines: Targets and Agents in Development**

Ion channels represent a significant opportunity to address an underexploited class of therapeutic targets. Nearly 150 novel ion channel modulators are reported to be in clinical development. The report provides a comprehensive analysis of the ion channel modulator pipeline, breaking it down by company, ion channel type, and therapeutic indication.

- Ion channel modulators in clinical development and their potential
- Improved molecular understanding of ion channel structure and cellular activity
- High-throughput screening methods for identification of novel modulators
- Prospects for ion channel modulators and commercial successes to date
- Pipeline activities, expert views, and survey results

*Published: September 2009*

*Length: 154 pages*

## **Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment**

In the nearly 35 years since the first process for creating mAbs was introduced, they have remained a centerpiece of the growing biotechnology industry. The report reviews the broad drug development effort that is focused on bringing improved mAb-based products to the market, concentrating on those used for therapeutic applications. It surveys the latest technologies being applied to the development of these compounds and profiles the major companies, drugs, and projects.

- Future products and their indications
- Merits of human versus chimeric structures
- Costs of mAb therapy and the US healthcare debate
- Clinical pipeline with over 250 candidates
- A focus on "engineered" antibodies

*Published: August 2009*

*Length: 187 pages*

## **Data Mining in Drug Development and Translational Medicine**

The biopharmaceutical industry is grappling not only with sheer data volume but with the ability of researchers to extract information through identification and contextual analysis of those data that are relevant to a particular set of investigations. The report examines data mining challenges and approaches in pharmaceutical R&D.

- Techniques, technology, and software used in life science data mining
- Data mining for early preclinical safety assessments
- Data mining in clinical trials
- Data mining in pharmacovigilance
- Business models and solutions in drug development bioinformatics

*Published: July 2009*

*Length: 114 pages*

## **Next-Generation Sequencing: Solving the Genome**

Next-generation sequencing (NGS) technologies are advancing in quality and applications diversity at a breathtaking pace. The market is diversifying strongly into labs without previous involvement in sequencing. The report provides a detailed overview of the technologies involved in next-generation sequencing, starting with the four systems currently on the market and continuing with those now in development.

- Current NGS platforms and how they compare
- Market dynamics and competitive landscape for new entrants
- Next-generation systems in development
- Bioinformatics issues
- Applications of NGS
- User survey results and views of interviewees

*Published: June 2009*

*Length: 164 pages*

## **Molecular Diagnostics: A Dynamic and Rapidly Broadening Market**

Molecular diagnostic applications in the areas of oncology, personalized medicine, inherited disorders, prediction of genetic disease risk, and many others are rapidly increasing in number as this burgeoning field expands beyond infectious disease testing. The report analyzes the emerging applications and technologies, marketplace trends, and business considerations for companies in this space.

- Established and up-and-coming technologies
- The activities of more than 35 companies
- More than 300 current and emerging molecular diagnostic tests for disease applications and genetic testing
- Business considerations associated with product development, commercialization, and marketing
- Regulatory issues
- Challenges facing companies developing molecular diagnostics and/or companion diagnostics and targeted therapies
- Major trends in the molecular diagnostics market, such as the increasing number of tests that are commercially available
- Interview transcripts with industry experts

*Published: January 2009*

*Length: 284 pages*

# Cost-Effective Access to Business Intelligence

- **Corporate Global License Program**
- **Company Site License Program**

To make better decisions in a rapidly changing economy, executives require access to expert business and market intelligence. To meet this need, *Insight Pharma Reports* introduces its **Corporate Global License** and **Company Site License** programs. These two programs are designed to provide our customers with greater access to a large portfolio of business assessment reports.

## **Corporate Global License Program**

- Up to a 50% reduction in price when purchasing multiple global licenses
- Worldwide access to all employees for each report purchased
- Control costs and maximize budgets through coordinated purchases and reduced duplicates
- Maximize the dissemination of information with a searchable PDF on your corporate Intranet
- Ideal program for multinational organizations
- Receive discounts on CHI conferences and Barnett International publications

## **Company Site License Program**

- Up to a 50% reduction in price when purchasing 3 or more single site licenses
- Full site access to all employees for each report purchased
- Maximize the dissemination of information with a searchable PDF on your corporate Intranet
- Ideal program for small to mid-sized organizations
- Receive discounts on CHI conferences and Barnett International publications

*Insight Pharma Reports* has developed and maintained a very impressive and loyal client base, including senior level executives, global competitive intelligence executives, librarians, information specialists, and research scientists.



For a complimentary consultation on how we might be able to help you with your information needs, while helping you stay within your budget, please contact:

**David Cunningham**  
**Global Report Sales**

**Tel: 781-972-5472 • E-mail: [cunningham@healthtech.com](mailto:cunningham@healthtech.com)**

**[InsightPharmaReports.com](http://InsightPharmaReports.com)**

# Order Form

Order these reports at [www.InsightPharmaReports.com](http://www.InsightPharmaReports.com), or fax or mail this form with payment to:  
 Insight Pharma Reports, Attn: Rose LaRaia, 250 First Avenue, Suite 300, Needham, MA 02492 • 781-972-5444, Fax: 781-972-5424

## REPORTS

	Print Copy	Single-Site License PDF
<b>Multiplex Assays: Evolving Technologies, Applications and Future Directions</b> January 2010, 190 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Strategic Alliances: Synergistic Path to Value Creation</b> January 2010, 120 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response</b> Nov. 2009, 350 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Immunotherapies and Vaccines for Nontraditional Indications</b> October 2009, 224 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Strategic Alliances: The Driving Forces Behind the Deals</b> October 2009, 126 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Ion Channel Modulator Pipelines: Targets and Agents in Development</b> Sep. 2009, 154 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment</b> August 2009, 187 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Outsourcing Preclinical Studies to China: Benefits and Challenges</b> July 2009, 112 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Data Mining in Drug Development and Translational Medicine</b> July 2009, 114 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Next-Generation Sequencing: Solving the Genome</b> June 2009, 164 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Pharmacogenomics: Delivering on the Promise</b> June 2009, 184 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Bioinformatics and Computational Biology</b> June 2009, 134 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Approaches to Reducing Phase II Attrition</b> May 2009, 160 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Medicinal Chemistry for Drug Discovery: Significance of Recent Trends</b> Mar. 2009, 170 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Direct-to-Consumer Genetic Testing: Business Prospects in the United States</b> Mar. 2009, 336 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Protease Inhibitors: Innovation Drives Drug Pipeline</b> Feb. 2009, 156 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Molecular Diagnostics: A Dynamic and Rapidly Broadening Market</b> Jan. 2009, 284 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Biomedical Imaging: From Drug Target Discovery to Medical Diagnostics</b> Dec. 2008, 154 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Neurodegenerative Diseases: Next-Generation Drugs for Four Major Disorders</b> Dec. 2008, 148 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>European Clinical Trial Site Options: An Insider's Analysis</b> Dec. 2008, 250 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Stem Cells Come of Age</b> Nov. 2008, 200 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Immunotherapies and Vaccines for Cancer and Infectious Diseases</b> Oct. 2008, 390 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>GPCRs: Dawn of a New Era?</b> Oct. 2008, 192 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Obesity Drug Pipeline: Developing Therapies for a Complex Disease</b> Sep. 2008, 104 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Strategic Mgmt. of Resources &amp; Portfolios: Structuring Risk to Maximize Opportunity in R&amp;D</b> Aug. 2008, 110 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Cancer Biomarkers: Adoption Is Driving Growth</b> July 2008	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Antibiotic R&amp;D: Resolving the Paradox between Unmet Medical Need &amp; Commercial Incentive</b> July 2008, 172 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Systems Biology: A Disruptive Technology</b> May 2008, 156 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00
<b>Cardiotoxicity: Issues, Technologies, and Solutions for the Future</b> May 2008, 270 pp	<input type="checkbox"/> \$2,995.00	<input type="checkbox"/> \$3,750.00

\*Insight Pharma Reports single-site and country licenses are multi-user, searchable, cut-and-paste ready PDFs. Contact David Cunningham ([cunningham@healthtech.com](mailto:cunningham@healthtech.com)) for global licensing

**Purchase 2 reports—10% discount    Purchase 3 reports—15% discount    Purchase 4 reports—20% discount**

\*Insight Pharma Reports single-site and country licenses are multi-user, searchable, cut-and-paste ready PDFs. Contact David Cunningham ([cunningham@healthtech.com](mailto:cunningham@healthtech.com)) for global licensing

Choose a payment option:

1.  Enclosed is a check payable to CHI, in U.S. currency. (In Massachusetts, add 6.25% sales tax.)
2.  Purchase order number \_\_\_\_\_
3.  Please charge     AMEX     Visa     MasterCard

Card #: \_\_\_\_\_ Exp. Date: \_\_\_\_\_ Security Code: \_\_\_\_\_

Cardholder: \_\_\_\_\_ Signature \_\_\_\_\_

Mr.     Ms.     Mrs.     Dr.    First Name \_\_\_\_\_ Last Name \_\_\_\_\_

Job Title: \_\_\_\_\_ Div./Dept. \_\_\_\_\_ Company \_\_\_\_\_

Address: (Please include Mail Stop, Room, or Bldg. #): \_\_\_\_\_

City/State/Postal Code: \_\_\_\_\_ Country \_\_\_\_\_

Telephone: \_\_\_\_\_ Fax: \_\_\_\_\_ E-Mail: \_\_\_\_\_

Total: \$ \_\_\_\_\_

### TO ORDER:

Web: [InsightPharmaReports.com](http://InsightPharmaReports.com)

Phone: 781-972-5444

Fax: 781-972-5425

E-mail: [rlaraia@healthtech.com](mailto:rlaraia@healthtech.com)

Mail: Cambridge Healthtech Institute  
 Rose LaRaia  
 250 First Avenue, Suite 300  
 Needham, MA 02494